A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension

Trial Profile

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2013

At a glance

  • Drugs Azilsartan medoxomil/chlortalidone (Primary) ; Azilsartan medoxomil; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 17 Jun 2013 Pooled analysis presented at the 23rd European Meeting on Hypertension.
    • 29 Aug 2012 Primary endpoint 'Systolic-blood-pressure' has been met based on results reported in the American Journal of Medicine.
    • 29 Aug 2012 Results published in the American Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top